A dedicated GvHD clinic may improve the quality of life for allogeneic stem cell transplant survivors


  • Conflict of interest: FLD and BES have received research funding and honoraria from Therakos, a Johnson and Johnson company. The other authors have no conflict of interest to declare.

No abstract is available for this article.